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Gene polymorphismBackground: End stage renal disease (ESRD) is a common cause of morbidity and mortality among chil-
dren. Interleukin 4 is a cytokine that might influence the progression of chronic kidney disease (CKD) to
end stage renal disease. There are variable number of tandem repeats (VNTRs) in IL4 gene that could play
major roles in genetic predisposition to some diseases. Aim of the study: The purpose of this study is to
detect the association of allelic variant in intron 3 VNTR-IL4 gene with the end stage renal disease and if
these variants could be considered as risk markers for this disease.
Subjects and methods: The study was conducted on fifty-five children with CKD and fifty healthy children
served as controls. All participants were genotyped for intron 3 VNTR by Polymerase Chain Reaction.
Results: The frequency of intron 3 VNTR-IL4 P1P2 + P2P2 genotypes was significantly higher in ESRD-
children than those with P1P1 genotype (88.7% vs. 15.4%, OR 43; 95% CI 13–134, P value < 0.001). Also,
the frequency of P2 allele was significantly higher in ESRD-children compared with healthy controls
(70.9% vs. 8%, OR 28; 95% CI 12–64, P value < 0.001). Furthermore, a significantly higher frequencies of
P1P1 genotype and P1 allele among the control group were demonstrated (84.6% vs. 11.3%, P < 0.001
and 92% vs. 29.1%, P < 0.001, respectively).
Conclusion: we concluded that the P2 allele is an allelic variant predisposing to ESRD in children with
CKD and it could be considered a risk factor for the development of ESRD.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
End stage renal disease is the irrecoverable decline of renal
function, resulting from various factors including, hypertension,
autoimmune diseases, diabetes mellitus, inherited disorders and
congenital abnormalities, with heterogeneous etiology whether
genetic or environmental. Inflammation is an important patho-
physiological factor in primary renal disease and leads to the
development of ESRD [1]. The affected kidney is struggling by
increasing filtration capacity until only 10–15% of kidney function
remains. The kidneys lose their regulatory and excretory function
resulting in uremic syndromes. Whether renal disease is acute or
chronic and regardless of the underlying pathological immune
response (innate or adaptive), it is clear that inflammatory cytoki-
nes have crucial role not only as mediators of immune responseand initiators of renal injury but also as immune modulators that
can abrogate the development of renal disease [2].
One of these cytokines is T-helper 2 Interleukin-4 (IL4) with its
dual role in the pathogenesis of renal disease, by both promoting
and limiting renal disease progression [3]. IL4 is the principal
mediator of immediate hypersensitivity reactions also it is the
main stimulator of B cell Ig heavy chain switching to the IgE iso-
type [4]. In addition, the evolution of Th2 cells from naïve CD4+
T cells is stimulated by IL-4 which also served as an autocrine
growth factor for these cells. At the same time, IL-4 suppresses
the Th1 cell evolution from its mother naïve CD4+ T cells, that is
to say, enhancing humoral immune response through antibody
production and inhibiting cell mediated immunity. Furthermore,
IL-4 inhibits the production of the proinflammatory cytokines such
as Tumor necrosis factor-a, Interleukin-6 and Interleukin-1a and
destructive enzymes by monocytes and this highlights its potent
anti-inflammatory effect [5]. With the same respect IL-4 may con-
trol the inflammation induced by Th17, which plays a fundamental
role in the pathogenesis of many autoimmune diseases [6].
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some 5 [7]. There are variable number of tandem repeats (VNTRs)
in cytokine genes and several specific single nucleotide polymor-
phisms (SNPs) that could play major roles in genetic predisposition
to some diseases and cancers. A variable number of tandem repeat
(VNTR) polymorphism is located in the third intron of IL-4 gene [8].
Also IL-4-590 promoter polymorphism, representing a C-to-T base
substitution at 589 base pair (bp) upstream of the transcriptional
site, has been identified [9]. Recent investigations have revealed
that some of these polymorphisms could alter the cytokines pro-
duction levels for instance, the 70-base-pair (bp) VNTR polymor-
phism in the third intron of the IL4 gene may alter the
expression level of this gene. Three alleles for the IL4 gene VNTR
polymorphism have been reported: RP*1 allele, three repeats;
RP*2 allele, two repeats; and RP*3 allele, four repeats. The RP*1
allele is more frequent than RP*2 allele and RP*3 allele is the rarest
one, which has been observed in few populations [10].
Association studies of VNTR polymorphism of the IL-4 gene
were carried out in many studies among different populations with
multiple different diseases with conflicting results [11,12,4,13].
This study was conducted to determine the relevance of the 70-
bp VNTR polymorphism of intron-3 of the IL-4 gene to the develop-
ment and progression of ESRD in children and whether these allelic
variants could be used as risk biomarkers of this disease.2. Patients and methods
Fifty-five pediatric patients with advanced chronic kidney dis-
ease (CKD) [stage 5] based on estimated glomerular filtration rate
(eGFR) according to the National Kidney Foundation classification
[14] were included in the study, selected from the hemodialysis
unit of the Center of Pediatric Nephrology and Transplantation
(CPNT), Children’s Hospital, Cairo University and 50 healthy chil-
dren attended the pediatric clinic of the National Research Centre
(NRC) with no clinical signs of renal disease and no family history
of renal disease served as controls. The study was done from 2013
to 2016. The inclusion criteria for hemodialyzed patients (HD)
includes: onset of hemodialysis below 18 years of age with at least
6 months duration on maintenance hemodialysis (MHD), they
were treated with hemodialysis for 3–4 h three times weekly with
a polysulfone membrane using bicarbonate-buffered dialysate. The
exclusion criteria: children with ESRD on hemodialysis less than
6 months. An informed consent for genetic studies was obtained
from parents of all participants. The protocol of the study was read
and approved by the Ethics Committee of NRC in Egypt. The work
has been carried out in accordance with The Code of Ethics of TheTable 1
Clinical and biochemical characteristics of the studied group.
ESRD-patients
(n = 55)
Age(years) 13.7 ± 3.4
Sex (male/female) 28 (50.9%)/27 (49.1%)
Duration of dialysis (years) 3.3 ± 2.4
Kt/v 1.8 ± 0.2
Predialysis – SBP (mmHg) 126 ± 16.0
Predialysis – DBP (mmHg) 80 ± 9.7
Postdialysis – SBP (mmHg) 115 ± 12.9
Postdialysis – DBP (mmHg) 74 ± 8.7
Predialysis-urea (mg/dl) 113.2 ± 37.2
Postdialysis-urea (mg/dl) 23.3 ± 9.2
Calcium (mg/dl) 8.7 ± 1.1
Phosphorus (mg/dl) 4.6 ± 1.5
Albumin (g/dl) 3.5 ± 0.5
Values are presented as mean ± SD or percentage as applicable. P-value < 0.05 is statistic
applicable. Kt/v: Adequacy of dialysis.World Medical Association (Declaration of Helsinki) for experi-
ments in humans.
A peripheral blood sample was obtained from HD and healthy
children. An immediate centrifugation was done for 10 min at
5000 rpm at 4 C. The centrifuged serum was transferred into ster-
ile tubes. All samples were stored at 20 C until assay. One ml of
venous blood sample was collected in EDTA vials for the extraction
of genomic DNA. The following parameters were measured: crea-
tinine, urea, calcium, phosphorus and albumin by routine methods
using (Olympas AU 400: Olympus diagnostic, Japan).
2.1. Determination of intron 3 VNTR-IL4 gene polymorphism
Genomic DNA was extracted from EDTA–anticoagulated whole
blood samples using the QIAamp DNA Mini isolation kit (QIAGEN,
#51304) following manufacturer’s instructions and was stored at
20 C until the analysis.
2.2. PCR-genotyping of intron 3 VNTR-IL4 gene polymorphism
DNA concentration was determined by Nano Drop 2000c Spec-
trophotometer (Thermo Fisher). Genomic DNA was amplified using
polymerase chain reaction (PCR). Amplification was carried out on
Veriti thermal cycler Applied Biosystems (USA). A 25 ll reaction
mixture in 0.2 ml thin-wall PCR strip tubes (Axygen Scientific,
Inc., CA) containing 200 ng genomic DNA, 12.5 ll master mix using
Hot-Star-Taq Plus DNA Polymerase (250 units) Catalog No. 203603.
(PE Applied Biosystems), 5 pmol each forward and reverse primers.
PCR was performed using:
forward primer 50 TAGGCTGAAAGGGGGAAAGC-30 and
reverse primer 50-CTGTTCACCTCAACTGCTCC-30.
The following reaction conditions were used: 95 C for 10 min;
32 cycles of 94 C for 30 s, 60 C for 30 s and 72 C for 30 s followed
by one cycle of 72 C for 5 min. The PCR products were analyzed
directly by electrophoresis on 2% agarose gels stained with ethid-
ium bromide. Alleles of 183 and 253 base pairs (bp) in lengths were
recognized as allele P1 and P2, respectively [15].
2.3. Statistical analysis
Data were processed and analyzed using the Statistical Package
of Social Science (SPSS) for windows, version 17.0 (SPSS Inc., Chi-
cago, IL). Nominal data were summarized as frequencies (percent-
ages). Associations between Nominal data were investigated usingControls
(n = 50)
P-value
13.0 ± 3.4 0.3
30 (60%)/20 (40%) 0.2
114 ± 4.9 <0.001
74 ± 4.9 <0.001
NA
NA
24.0 ± 5.0 <0.001
NA
9.4 ± 0.8 <0.001
3.9 ± 0.6 0.08
4.0 ± 0.2 <0.001
ally significant. SBP: Systolic blood pressure, DBP: Diastolic blood pressure, NA: Non
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fidence interval (95% CI). Numerical data were represented as
mean and standard deviation. Differences between groups were
detected using Student’s t-test. p Value of <0.05 was considered
statistically significant. The distributions of the allelic and geno-
typic frequencies of the studied SNP respected the Hardy–Wein-
berg equilibrium.3. Results
Clinical and biochemical characteristics of the studied groups
were summarized in table 1. The mean age of the 55 ESRD- chil-
dren (28 males& 27 females) included in this study was
13.7 ± 3.4 years with mean duration of dialysis was 3.3 ± 2.4 years.
The mean age of the 50 healthy children (30 males & 20 females)
was 13.0 ± 3.4 years.
There were no significant differences between the groups with
respect to age, sex ratio, urea and phosphorus serum levels. There
were statistically significant differences between ESRD- patients
and controls regarding predialysis systolic and diastolic blood
pressure, calcium and albumin levels (P-value < 0.001).
The distribution of intron 3 VNTR-IL4 genotype frequencies,
allele frequencies and risk association were compared between
ESRD-children and controls and summarized in Table 2.
Statistically significant differences were demonstrated regarding
the intron 3 VNTR-IL4 genotypes between the two groups, where
the P1P2 + P2P2 genotypes frequencies were higher in the
ESRD-patients while the P1P1 genotype frequency was higher in
the control subjects (88.7% vs. 15.4%, OR 43; 95% CI 13–134, PTable 2
The frequency distribution and risk association of intron 3 VNTR-IL4 genotypes and allele
Gene ESRD-patients Contr
(n = 55) (n = 5
Genotypes
P1P1 8 (14.5%) 44 (8
P1P2 31 (56.4%) 2 (4%
P2P2 16 (29.1%) 4 (8%
P1P1 8 (15.4%) 44 (8
(n = 52)
43 (1
P1P2 + P2P2 47 (88.7%) 6 (11
(n = 53)
Alleles (n = 110) (n = 1
P1 32 (29.1%) 92 (9
P2 78 (70.9%) 8 (8%
Data were evaluated by the gene counting method. Values are presented as percentage.
* Odd’s ratio was used.
Table 3
Comparison of clinical and biochemical characteristics between carriers of P2 allele and n
P1P2 + P2P2
(n = 53)
Age (years) 13.6 (5–18)
Sex (male/female) 29 (54.7%)/24 (45.3%)
Predialysis – SBP (mmHg) 123.3 (100–170)
Predialysis – DBP (mmHg) 78.7 (60–100)
Postdialysis – SBP (mmHg) 114.6 (90–150)
Postdialysis – DBP (mmHg) 73 (60–100)
Predialysis-urea (mg/dl) 103 (14–185)
Postdialysis-urea (mg/dl) 24 (9–46)
Calcium (mg/dl) 8.9 (5.9–13.6)
Phosphorus (mg/dl) 4.6 (1.5–7)
Albumin (g/dl) 3.6 (2.5–4.6)
Data are presented as mean (minimum/maximum) or percentage as applicable. P was svalue < 0.001). Similarly, there were statistically significant differ-
ences regarding P1 and P2 alleles frequencies, where P2 allele dis-
play a higher frequency among the ESRD-patient group (70.9% vs.
8%, P value < 0.001). Furthermore, we demonstrated a significantly
higher frequency of P1P1 genotype and P1 allele among the control
group (84.6% vs. 11.3%, P < 0.001 & 92% vs. 29.1%, P < 0.001, respec-
tively). Demonstration of the risk association of the different intron
3 VNTR-IL4 genotypes, alleles and ESRD among studied groups
showed that children with [P1P2 and P2P2 genotypes] have 43
times more risk to develop ESRD than those with P1P1 genotype
(OR 43; 95% CI 13–134). Moreover, carriers of mutant P2 allele
have 28 times more risk to develop ESRD than those with the wild
P1 allele (OR 28; 95% CI 12–64).
Comparison of clinical and biochemical characteristics between
the carriers of the P2 allele (P1P2 + P2P2 genotypes) and non
carriers (P1P1 genotype) is shown in Table 3. There were statisti-
cally significant differences between the two groups regarding
Pre-dialysis systolic blood pressure and urea (P 0.03 & <0.001
respectively) where carriers of P2 allele exhibit higher levels of
these parameters than the non carriers.4. Discussion
End-stage renal disease (ESRD) is associated with high rates of
morbidity and mortality, and increased health care use [16]. Sub-
stantial evidence suggests that ESRD could be considered a chronic
systemic inflammatory state, and inflammation may be an impor-
tant pathophysiological factor in primary renal disease and its pro-
gression towards ESRD. Although many etiological factorss among the studied groups.
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tion and inflammatory cytokines have negotiable role in its patho-
genesis acting not only as immune modulators initiating renal
injury but also as mediators that ameliorate renal damage. IL-4 is
a potent anti-inflammatory cytokine that reduces the production
of destructive enzymes and proinflammatory cytokines [4].
Genetic factors that affect this cytokines may play fundamental
roles in the development of ESRD. IL-4 VNTR located in intron 3 of
IL-4 gene and could alter messenger ribonucleic acid splicing,
which leads to different splice variants [8]. Some studies suggested
the possible association between P1 allele and higher expression of
the IL-4, other studies reported the association between P2/P2
genotype and lower expression of this cytokine [10]. In this study,
the frequencies of the intron 3 VNTR-IL4 P1P2 + P2P2 genotypes
were significantly higher among ESRD-children than those with
P1P1 genotype. Also, the frequency of P2 allele was significantly
higher in ESRD- patients compared with healthy controls indicat-
ing that the P2 allele may be considered as an allelic variant predis-
posing to ESRD in children with CKD and a risk factor for the
development of ESRD. Moreover, we demonstrated a significantly
higher frequency of P1P1 genotype and P1 allele among the control
group. Although the frequency of P1 allele, which was supposed to
lead to over expression of IL-4 observed in many inflammatory,
autoimmune diseases and cancers [17,18], yet in this study we
supposed that the wild allele P1 is protective against the develop-
ment of ESRD by combating the inflammatory process by its high
production. With the same respect, IL4 is claimed to be a potent
anti- inflammatory cytokine with its critical role in the regulation
of TH0 cell differentiation stimulating Th2 immunity and inhibit-
ing Th1 responses. Furthermore IL-4 provokes a macrophage phe-
notype that has greater scavenger receptor activity and increased
release of anti-inflammatory and fibrogenic factors, supporting
its significant role in the clearance of cell debris and promotion
of tissue repair [19].
In concordance with our result, Vasudevan et al. (2011) con-
cluded that VNTR polymorphism of the IL-4 gene is a risk factor
for the development of ESRD among Malaysians [11]. Similarly,
Mittal and Manchanda (2007) reported that the frequency of
P2P2 genotype was higher in ESRD- patients as compared to con-
trols (62.7% vs 46.7%) [4].
Since diabetes mellitus is known to be one of the leading factors
for the development of renal impairment, Tripathi 2015, studied
the impact of VNTR IL4 genetic polymorphism on type 2 Diabetes
Mellitus demonstrating that the genotype P2/P2 frequency was
significantly higher in patients as compared to healthy controls
(60.00% vs. 49.04%) [20]. Also, Bid et al. 2008 reported that IL-4
P2P2 genotype was higher in patients of diabetes type 2 with odds
ratio 2.30 [21]. Moreover, murine model showed that a mice trea-
ted with IL4 had improved insulin sensitivity and glucose tolerance
while lipid accumulation in adipose tissues was inhibited [22].
Similar results were also reported in other diseases where, Sal-
imi et al. (2014) declared that the P2 allele was found more preva-
lent in preeclampsia patients in comparison with healthy subjects
[10].
With respect to IL4 impact on cancer development, progression
and treatment, IL4 is advertised as a potent anti-apoptotic cytokine
and survival factor for tumour cells helping these cells to evade the
apoptotic effect of anti-tumour therapies with consequent resis-
tance to cancer treatments. Conversely, IL-4 has been investigated
as a therapeutic agent in cancer, through its perchance toxicity on
some tumour cells. Subsequently, intron 3 VNTR-IL4 polymor-
phism could influence the risk of human cancer. Similar result to
ours, Tsai et al. (2005) suggested that intron 3 VNTR- IL4 gene poly-
morphism was a potential genetic marker for the risk of bladder
cancer [23]. On other hand, Duan et al. (2014) announced that P1
allele might be a risk factor for several malignancies [24]. Likewise,Ahmed et al. (2016) reported that the frequency of P1 allele was
found higher in leukemic patients than control group and the car-
riers of P1 allele were at 1.24 times more risk to develop leukemic
disease compared to P2 carriers [25].
Another contradictory findings were reported in Behcet disease
(BD) where Inanir et al. (2013) suggest that possession of the P1
allele of the IL4 gene 70 bp VNTR polymorphism may constitute
a risk for developing BD [26].
In children, Intron 3 VNTR-IL4 gene polymorphism was studied
in Japanese patients with IgA nephropathy to clarify the impact of
this polymorphism on progression of this disease to ESRD and
announced that although there was no difference between the
IgA nephropathy and healthy control groups regarding the fre-
quencies of both IL4 VNTR allele and genotype yet the frequencies
of IL4 P1 allele and P1/P1 genotype in patients with progressive IgA
nephropathy children (end-stage renal disease) were significantly
greater than corresponding values in the non-progression group.
This result could highlight the debate about the role of IL4 in the
pathogenesis and progression to ESRD [27].
To conclude, a P2 allele of the intron 3 VNTR-IL4 gene polymor-
phism showed a significantly higher frequency in children with
CKD and could be used as a risk marker for the development of
ESRD. Meanwhile, the wild P1 allele is protective against the devel-
opment of ESRD. However, The mechanisms that drive the devel-
opment of ESRD among children with chronic kidney disease
with the contribution of environmental and genetic factors require
linking immune and inflammatory mechanisms with more atten-
tion and clarification of the role of cytokines and their genetic poly-
morphisms to outline some of the common therapies used to
target renal disease with an emphasis on their potential to sup-
press inflammation and immune system function.
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the institu-
tional research committee at which the studies were conducted
(IRB approval number 13 169) and with the 1964 Helsinki declara-
tion and its later amendments or comparable ethical standards.
Informed consent was obtained from all participants the study
included.Conflict of interest
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